Indivior Plc (INDV)

$29.13 +3.89 (15.41%)
Market Cap 3.48B
Revenue (ttm) 1.19B
Net Income (ttm) 2.00M
EPS (ttm) N/A
PE Ratio 13.99
Forward PE 14.48
Profit Margin 0.17%
Debt to Equity Ratio -1.27
Volume 10,663,200
Avg Vol 2,123,940
Day's Range N/A - N/A
Shares Out 137.88M
Stochastic %K 79%
Beta 0.70
Analysts Strong Sell
Price Target $29.40

Company Profile

Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; SUBOXONE Film, a buprenorphine and naloxone sublingual film; SUBOXONE Tablet, a buprenorp...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 804 379 1090
Address:
10710 Midlothian Turnpike, Suite 125, North Chesterfield, United States
EchoBolt
EchoBolt Oct. 30 at 10:01 PM
$INDV
0 · Reply
SlatsMcSlappy
SlatsMcSlappy Oct. 30 at 9:37 PM
$INDV .72A vs .38E 3Q25, .54 3Q24 Revenues were 21% over est Raised revenue and earnings guidance
0 · Reply
howardlindzon
howardlindzon Oct. 30 at 5:37 PM
$INDV the ozempic of opiodes still working
0 · Reply
howardlindzon
howardlindzon Oct. 30 at 5:36 PM
$INDV shoulda coulda
1 · Reply
7o4
7o4 Oct. 30 at 3:08 PM
$INDV ha ☺️ ⌚
0 · Reply
thetrackisfast
thetrackisfast Oct. 30 at 11:55 AM
$INDV yup! Those inside days!
0 · Reply
thetrackisfast
thetrackisfast Oct. 20 at 4:42 PM
$INDV definitely NOT an inside day
0 · Reply
thetrackisfast
thetrackisfast Oct. 20 at 3:28 PM
$INDV possible inside day big drop in volume
1 · Reply
AcrossMarkets
AcrossMarkets Oct. 17 at 9:17 PM
Addex Therapeutics (NASDAQ: $ADXN) is catching eyes! With low float, a strategic collaboration with Indivior ($INDV), and potential $330M milestone payments, traders are buzzing. Do you think ADXN is about to skyrocket or will it retrace? 🔥 Full story 👉 https://www.acrossmarkets.icu/2025/10/addex-therapeutics-adxn-soars-on.html
2 · Reply
thetrackisfast
thetrackisfast Oct. 15 at 6:14 AM
$INDV was inside 10/13
0 · Reply
Latest News on INDV
Indivior PLC (INDV) Q3 2025 Earnings Call Transcript

Oct 30, 2025, 3:56 PM EDT - 6 hours ago

Indivior PLC (INDV) Q3 2025 Earnings Call Transcript

Indivior Reports Third Quarter 2025 Financial Results and Raises Full-Year 2025 Financial Guidance

Oct 30, 2025, 7:00 AM EDT - 15 hours ago

Indivior Reports Third Quarter 2025 Financial Results and Raises Full-Year 2025 Financial Guidance

Indivior to Participate in the Stifel 2025 Healthcare Conference

Oct 28, 2025, 10:00 AM EDT - 2 days ago

Indivior to Participate in the Stifel 2025 Healthcare Conference

Indivior to Report Third Quarter 2025 Financial Results and Host Webcast on October 30th

Oct 16, 2025, 4:04 PM EDT - 14 days ago

Indivior to Report Third Quarter 2025 Financial Results and Host Webcast on October 30th

Clinical Evidence Supports Rapid SUBLOCADE® Induction as a Strategy to Improve Retention in Opioid Use Disorder Treatment

Oct 15, 2025, 8:00 AM EDT - 15 days ago

Clinical Evidence Supports Rapid SUBLOCADE® Induction as a Strategy to Improve Retention in Opioid Use Disorder Treatment

UK's Indivior to re-domicile to US after listing move

Oct 1, 2025, 9:35 AM EDT - 4 weeks ago

UK's Indivior to re-domicile to US after listing move

Indivior Proposes New Corporate Structure to Achieve U.S. Domiciliation

Oct 1, 2025, 8:00 AM EDT - 4 weeks ago

Indivior Proposes New Corporate Structure to Achieve U.S. Domiciliation

Indivior PLC (INDV) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 8, 2025, 11:44 AM EDT - 7 weeks ago

Indivior PLC (INDV) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Indivior to Participate in Upcoming Investor Events

Aug 20, 2025, 12:00 PM EDT - 2 months ago

Indivior to Participate in Upcoming Investor Events

Indivior's Strategic Turnaround Gains Traction Post-Q2 2025

Aug 5, 2025, 5:39 PM EDT - 3 months ago

Indivior's Strategic Turnaround Gains Traction Post-Q2 2025

Indivior PLC (INDV) Q2 2025 Earnings Call Transcript

Aug 1, 2025, 5:22 AM EDT - 3 months ago

Indivior PLC (INDV) Q2 2025 Earnings Call Transcript

Indivior Reports Second Quarter 2025 Financial Results and Raises FY 2025 Financial Guidance

Jul 31, 2025, 7:00 AM EDT - 3 months ago

Indivior Reports Second Quarter 2025 Financial Results and Raises FY 2025 Financial Guidance

Indivior Announces Completion of Cancellation of Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained

Jul 25, 2025, 2:00 AM EDT - 3 months ago

Indivior Announces Completion of Cancellation of Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained

Indivior Real World Evidence Study Finds Medications for Opioid Use Disorder, Particularly Extended-Release Buprenorphine, Reduced Odds of Emergency Department Visits for Patients with Opioid Use Disorder

Jul 23, 2025, 8:00 AM EDT - 3 months ago

Indivior Real World Evidence Study Finds Medications for Opioid Use Disorder, Particularly Extended-Release Buprenorphine, Reduced Odds of Emergency Department Visits for Patients with Opioid Use Disorder

Indivior to Report Second Quarter 2025 Financial Results and Host Webcast on July 31st

Jul 17, 2025, 9:00 AM EDT - 3 months ago

Indivior to Report Second Quarter 2025 Financial Results and Host Webcast on July 31st

Indivior Appoints Vanessa Procter as Executive Vice President of Corporate Affairs

Jul 8, 2025, 8:00 AM EDT - 4 months ago

Indivior Appoints Vanessa Procter as Executive Vice President of Corporate Affairs

Indivior Announces Inclusion in the U.S. Russell 2000® and 3000® Indexes

Jun 30, 2025, 7:00 AM EDT - 4 months ago

Indivior Announces Inclusion in the U.S. Russell 2000® and 3000® Indexes

Indivior Appoints Tony Kingsley to the Board of Directors

Jun 24, 2025, 4:12 PM EDT - 4 months ago

Indivior Appoints Tony Kingsley to the Board of Directors

Indivior Presents New Data at CPDD Demonstrating that High Buprenorphine Exposure May Improve Treatment Outcomes in High Fentanyl Users

Jun 19, 2025, 9:00 AM EDT - 4 months ago

Indivior Presents New Data at CPDD Demonstrating that High Buprenorphine Exposure May Improve Treatment Outcomes in High Fentanyl Users

Indivior to delist from London Stock Exchange, maintain Nasdaq listing

Jun 2, 2025, 2:33 AM EDT - 5 months ago

Indivior to delist from London Stock Exchange, maintain Nasdaq listing

Indivior Announces Intention to Cancel Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained

Jun 2, 2025, 2:00 AM EDT - 5 months ago

Indivior Announces Intention to Cancel Secondary Listing on London Stock Exchange; Primary Listing on Nasdaq to be Maintained

Indivior Announces Patrick Barry as Chief Commercial Officer

May 27, 2025, 8:30 AM EDT - 5 months ago

Indivior Announces Patrick Barry as Chief Commercial Officer

New Study Highlights Monthly SUBLOCADE® as a Potential Treatment Option for Opioid Use Disorder During and After Pregnancy

May 1, 2025, 10:27 AM EDT - 6 months ago

New Study Highlights Monthly SUBLOCADE® as a Potential Treatment Option for Opioid Use Disorder During and After Pregnancy

Indivior: Trying To Break Addiction

Apr 28, 2025, 12:12 PM EDT - 6 months ago

Indivior: Trying To Break Addiction

Indivior PLC (INDV) Q1 2025 Earnings Conference Call Transcript

Apr 24, 2025, 10:45 AM EDT - 6 months ago

Indivior PLC (INDV) Q1 2025 Earnings Conference Call Transcript

Indivior Announces Q1 2025 Financial Results

Apr 24, 2025, 2:00 AM EDT - 6 months ago

Indivior Announces Q1 2025 Financial Results

Indivior Announces Further Changes to Board of Directors

Mar 4, 2025, 8:40 AM EST - 8 months ago

Indivior Announces Further Changes to Board of Directors

UK's Indivior appoints Joe Ciaffoni as CEO

Feb 27, 2025, 2:48 AM EST - 8 months ago

UK's Indivior appoints Joe Ciaffoni as CEO

Indivior Announces Joseph Ciaffoni Appointed Chief Executive Officer

Feb 27, 2025, 2:00 AM EST - 8 months ago

Indivior Announces Joseph Ciaffoni Appointed Chief Executive Officer

Indivior Announces FDA Approval of Label Changes for SUBLOCADE® (buprenorphine extended-release) Injection

Feb 24, 2025, 2:00 AM EST - 8 months ago

Indivior Announces FDA Approval of Label Changes for SUBLOCADE® (buprenorphine extended-release) Injection

Indivior PLC (INDV) Q4 2024 Earnings Call Transcript

Feb 20, 2025, 2:26 PM EST - 9 months ago

Indivior PLC (INDV) Q4 2024 Earnings Call Transcript

European Addiction-Focused Indivior Stock Falls As Drugmaker Warns Lower Revenues In 2025 Despite Q4 Earnings Beat

Feb 20, 2025, 2:13 PM EST - 9 months ago

European Addiction-Focused Indivior Stock Falls As Drugmaker Warns Lower Revenues In 2025 Despite Q4 Earnings Beat

UK's Indivior forecasts 17% decline in 2025 revenue

Feb 20, 2025, 2:55 AM EST - 9 months ago

UK's Indivior forecasts 17% decline in 2025 revenue

Indivior Announces FY and Q4 2024 Financial Results

Feb 20, 2025, 2:00 AM EST - 9 months ago

Indivior Announces FY and Q4 2024 Financial Results

Indivior Statement RE: Delayed FDA Approval of SUBLOCADE® Label Changes

Feb 12, 2025, 2:00 AM EST - 9 months ago

Indivior Statement RE: Delayed FDA Approval of SUBLOCADE® Label Changes

Rapid Initiation with Once-monthly SUBLOCADE® Superior to Standard Initiation for Treating Opioid Use Disorder, Including in Fentanyl-Positive Patients, According to Data Presented at CSAM 2024

Nov 19, 2024, 12:52 PM EST - 1 year ago

Rapid Initiation with Once-monthly SUBLOCADE® Superior to Standard Initiation for Treating Opioid Use Disorder, Including in Fentanyl-Positive Patients, According to Data Presented at CSAM 2024

Indivior Responds to Publication of a Letter by Oaktree Capital Management to the Board of Indivior

Nov 7, 2024, 2:24 PM EST - 1 year ago

Indivior Responds to Publication of a Letter by Oaktree Capital Management to the Board of Indivior

Indivior Highlights Growing Body of Data on SUBLOCADE® (buprenorphine once-monthly extended-release injection) Helping Patients Achieve Long-Term Recovery from Opioid Use Disorder during Substance Abuse Prevention Month

Oct 30, 2024, 12:30 PM EDT - 1 year ago

Indivior Highlights Growing Body of Data on SUBLOCADE® (buprenorphine once-monthly extended-release injection) Helping Patients Achieve Long-Term Recovery from Opioid Use Disorder during Substance Abuse Prevention Month

Indivior PLC (INDV) Q3 2024 Earnings Call Transcript

Oct 24, 2024, 2:02 PM EDT - 1 year ago

Indivior PLC (INDV) Q3 2024 Earnings Call Transcript

Indivior Announces Q3 2024 Financial Results

Oct 24, 2024, 2:00 AM EDT - 1 year ago

Indivior Announces Q3 2024 Financial Results

Indivior: This Value Stock Has Over 100% Upside Potential If Market Share Stabilizes In 2025

Oct 13, 2024, 10:00 AM EDT - 1 year ago

Indivior: This Value Stock Has Over 100% Upside Potential If Market Share Stabilizes In 2025

British drugmaker Indivior cuts 2024 revenue forecast, shares fall

Oct 10, 2024, 7:33 AM EDT - 1 year ago

British drugmaker Indivior cuts 2024 revenue forecast, shares fall

Indivior Provides Preliminary Q3 2024 Results; Updates FY 2024 Guidance; Group Continues to Expect SUBLOCADE Peak Net Revenue of >$1.5 Billion

Oct 10, 2024, 7:00 AM EDT - 1 year ago

Indivior Provides Preliminary Q3 2024 Results; Updates FY 2024 Guidance; Group Continues to Expect SUBLOCADE Peak Net Revenue of >$1.5 Billion

Indivior's SUBLOCADE® Rapid Induction/Alternative Injection Site Prior Approval Supplement (PAS) Receives FDA Priority Review

Oct 7, 2024, 11:30 AM EDT - 1 year ago

Indivior's SUBLOCADE® Rapid Induction/Alternative Injection Site Prior Approval Supplement (PAS) Receives FDA Priority Review

EchoBolt
EchoBolt Oct. 30 at 10:01 PM
$INDV
0 · Reply
SlatsMcSlappy
SlatsMcSlappy Oct. 30 at 9:37 PM
$INDV .72A vs .38E 3Q25, .54 3Q24 Revenues were 21% over est Raised revenue and earnings guidance
0 · Reply
howardlindzon
howardlindzon Oct. 30 at 5:37 PM
$INDV the ozempic of opiodes still working
0 · Reply
howardlindzon
howardlindzon Oct. 30 at 5:36 PM
$INDV shoulda coulda
1 · Reply
7o4
7o4 Oct. 30 at 3:08 PM
$INDV ha ☺️ ⌚
0 · Reply
thetrackisfast
thetrackisfast Oct. 30 at 11:55 AM
$INDV yup! Those inside days!
0 · Reply
thetrackisfast
thetrackisfast Oct. 20 at 4:42 PM
$INDV definitely NOT an inside day
0 · Reply
thetrackisfast
thetrackisfast Oct. 20 at 3:28 PM
$INDV possible inside day big drop in volume
1 · Reply
AcrossMarkets
AcrossMarkets Oct. 17 at 9:17 PM
Addex Therapeutics (NASDAQ: $ADXN) is catching eyes! With low float, a strategic collaboration with Indivior ($INDV), and potential $330M milestone payments, traders are buzzing. Do you think ADXN is about to skyrocket or will it retrace? 🔥 Full story 👉 https://www.acrossmarkets.icu/2025/10/addex-therapeutics-adxn-soars-on.html
2 · Reply
thetrackisfast
thetrackisfast Oct. 15 at 6:14 AM
$INDV was inside 10/13
0 · Reply
JFDI
JFDI Oct. 14 at 3:17 PM
$INDV
0 · Reply
JFDI
JFDI Oct. 13 at 8:06 PM
$INDV High & Tight Alerts at 24.50 & 22
0 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 29 at 11:10 AM
$INDV Really good write-up that perfectly summarizes INDV's present situation. So if you want to bring your INDV knowledge up to date or just discover INDV, this is required reading. https://beyondspx.com/quote/INDV/analysis/indivior-s-strategic-reinvigoration-unlocking-sublocade-s-potential-amidst-market-shifts-nasdaq-indv
0 · Reply
SweepCastApp
SweepCastApp Sep. 29 at 10:33 AM
$INDV: Unusual Options Activity Alerted CALL flow observed 723x contracts at Strike price of $25 Exp on 10/17/2025 with Premium of $40K and showing BULLISH Sentiment
0 · Reply
StockConsultant
StockConsultant Sep. 26 at 2:34 PM
$INDV Indivior stock, nice setup and rally off the 22.22 support area, watch for an upcoming top of range breakout at https://stockconsultant.com/?INDV
0 · Reply
BellaDante5
BellaDante5 Sep. 26 at 12:14 AM
$INDV I had all my shares set to sell at $25 and it spiked to $25 on Webull. I’m not sure exactly how it happened because I don’t see any other spikes on other apps but I’ll buy back in in the $22 range. Easy money
0 · Reply
howardlindzon
howardlindzon Sep. 23 at 12:19 PM
$INDV wow. what’s the story here
0 · Reply
BellaDante5
BellaDante5 Sep. 23 at 7:12 AM
$INDV holy after hours
0 · Reply
BellaDante5
BellaDante5 Sep. 19 at 9:30 PM
$INDV let’s push back to $24.50 next week
0 · Reply
JarvisFlow
JarvisFlow Aug. 27 at 5:55 PM
Craig-Hallum updates rating for Indivior ( $INDV ) to Buy, target set at 27 → 34.
0 · Reply
kharlus
kharlus Aug. 19 at 9:58 PM
$INDV time for a pullback …
0 · Reply
Doozio
Doozio Aug. 15 at 3:23 PM
$INDV YO so 💪 it appears only chop n shakeouts to come. Hard to see a real correction wen a $PGNY is still chop chop huckleberries getting medicated thru XBI 🐒🍌🧠⏰♾️
0 · Reply